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RibavirinAbstract Background: The hepatitis C virus (HCV) epidemic is particularly devastating in Egypt
where its prevalence is about 12%. Chronic HCV infection can result in the accumulation of
immune complexes and stimulate antibodies, which can result in extrahepatic manifestations
(EHM).
Aim of the work: To assess the efﬁcacy and safety of combined pegylated interferon and ribavirin
therapy in the management of rheumatological EHM in HCV patients.
Patients and methods: Twenty-seven out of 50 consecutive HCV patients with rheumatologic
EHM were eligible and included in this study. All patients included in this study were subjected
to full history taking, clinical examination and laboratory investigations.
Results: The mean age of the patients was 43.8 ± 7.6 years. The clinical response of the patients
was: 2 patients (7.4%) were complete clinical responders, 5 (18.5%) were partial responders, 3
(11.1%) showed relapse and 17 (63%) were non-responders. There was a signiﬁcant improvement
in the number of patients with fatigue, polymerase chain reaction positivity and elevated liver
enzymes (p< 0.0001, p< 0.0001, p= 0.03, p= 0.01 respectively). There was no signiﬁcant corre-
lation between virological and clinical responses. There was a signiﬁcant correlation between viro-
logical and biochemical responses (p= 0.02). Minor side effects of the AVT developed in 13
(48.1%) patients: anemia (n= 5), mild thrombocytopenia (n= 8), ﬂu-like symptoms (n= 7) and
mild depression (n= 1).
54 A.K. El-Garf et al.Conclusion: Peg IFN and ribavirin did not improve HCV rheumatological extrahepatic manifes-
tations. Antiviral treatment may also induce or worsen autoimmune disorders and is sometimes
associated with major immune-mediated adverse events.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
An estimated 170 million individuals (3%) worldwide are
chronically infected with the hepatitis C virus (HCV) [1,2].
In the absence of treatment, 20% of them will develop cirrho-
sis or cancer [1,3].
The HCV epidemic is particularly devastating in Egypt
where the prevalence of HCV infection is about 12% [4,5].
HCV infection should be regarded as a systemic infectious dis-
ease with multiorgan involvement. More than 50% of HCV-
positive patients develop during the course of the disease at
least one extrahepatic manifestation (EHM). The EHMs are
often the ﬁrst and only clinical signs of a chronic hepatitis C
[6,7]. Evidence of HCV infection should always be sought
out in cases of unspeciﬁc chronic fatigue and/or rheumatic,
hematological, endocrine or dermatological disorders. It has
been reported to be associated with various rheumatic diseases
in Egypt as rheumatoid arthritis [8], systemic lupus erythe-
matosus [9] and vasculitis [10].
The goal of antiviral HCV therapy is to cure the infection
via a sustained elimination of the virus and to prevent liver
ﬁbrosis and end stage liver diseases (cirrhosis and hepatocellu-
lar carcinoma) [11]. The standard of care (SOC) for patients
with chronic hepatitis C virus (HCV) infection has consisted
of a combination of pegylated interferon (INF) plus ribavirin,
administered for 24–48-weeks depending on the HCV geno-
type. HCV therapy has been revolutionised by the approval
of two direct-acting antiviral agents (DAA) against the NS3/
4A serine protease for use in genotype 1 HCV, the protease
inhibitors boceprevir and telaprevir [12]. Accordingly, this
study aimed to assess the efﬁcacy and safety of combined pegy-
lated interferon and ribavirin therapy in the management of
rheumatological extrahepatic manifestations in HCV patients.
2. Patients and methods
Fifty consecutive unselected HCV patients with rheumatologic
extrahepatic manifestations were included in this study, from
the Rheumatology and Rehabilitation outpatient clinic, inpa-
tient department, Faculty of Medicine, Cairo University hospi-
tals and El-Kahera Al-fatemia hospital. Inclusion criteria for
the study were as follows: (a) Chronic HCV infection; (b)
The presence of HCV rheumatological extrahepatic manifesta-
tions; Exclusion criteria were: (a) The presence of hepatitis B
surface antigen; (b) The presence of rheumatic autoimmune
disease.
Treatment schedule consisted of weekly administration of
antiviral combination: Peginterferon (180 lg SC/week, or
1.5 lg/kg/week) + ribavirin 1000–1250 mg/day for at least
6 months. Informed consent was obtained for each patient
and the study was approved by the local ethics committee
and has been carried out in accordance with the declarationof Helsinki. Out of our 50 patients; twenty-three patients were
contraindicated to receive interferon (Five patients were above
60 years of age; Eight patients had decompensated liver dis-
ease; Three patients had severe anemia and not improved after
a course of iron supplement; 2 patients had coronary heart dis-
ease, 1 patient with psoriasis and 3 patients could not reduce
their body mass index to the range emitting administration
of interferon). The remaining 27 patients received treatment
for at least 6 months.
Before starting the antiviral combination all patients were
subjected to: full history taking, clinical examination (general
and full joint examination), calculation of the disease activity
score in 28 joints (DAS28) [13], complete laboratory investiga-
tions including: complete blood count (CBC), erythrocyte
sedimentation rate (ESR), serum rheumatoid factor (RF) by
the latex agglutination method, detection of circulatory
antinuclear antibodies (ANA) using the immunoﬂuorescence
technique, Liver function tests (alanine transaminase ‘ALT’,
aspartate transaminase ‘AST’, serum albumin, alkaline phos-
phatase), kidney function tests (urea, creatinine), complete
urine analysis and cryoglobulins, and quantitative reverse tran-
scriptase polymerase chain reaction (RT-PCR) (Applied
Biosystems, USA). Follow up of each patient includes: weekly
CBC and liver function tests during the ﬁrst month, then
monthly. After 12 weeks of treatment the quantitative PCR,
liver function tests, kidney function tests, TSH and fundus
examination were repeated. Treatment efﬁcacy: the response
to treatment was analyzed by comparing clinical, virologic
and immunologic parameters at the initial evaluation and at
the end of 6 months of antiviral treatment (AVT).
Statistical analysis: Data were coded and entered using the
statistical package SPSS version 15. Data were summarized
using descriptive statistics: mean ± standard deviation
(±SD), or frequencies (n) and percentages (%). Statistical dif-
ferences between groups were tested using Chi Square test (v2)
and McNemar test for qualitative variables, Independent sam-
ple t-test and ANOVA (analysis of variance) for quantitative
normally distributed variables and non-parametric Mann–
Whitney test and Kruskal Wallis test for non-normally dis-
tributed quantitative variables. Correlations were done to test
for linear relations between variables. A probability value
(p value) <0.05 was considered statistically signiﬁcant.3. Results
The 27 HCV patients with extrahepatic manifestations who
received combined antiviral therapy for at least 6 months
included 6 men and 21 women with a mean age of
43.8 ± 7.6 years (range 32–59 years). Main characteristics of
the 27 patients are detailed in Tables 1–3.
Treatment related data and outcomes: 6 months following
antiviral therapy, 15 patients (55.5%) had sustained virologic
Table 1 Characteristics of the 27 HCV patients with extrahepatic manifestations who received combined antiviral therapy for
6 months at least.
Characteristic HCV patients with EHM (n= 27)
Mean ± SD Range
Age (years) 43.8 ± 7.6 32–59
HCV duration (years) 4.3 ± 3.7 1–14
Joint aﬀection duration (year) 6.3 ± 6.5 1–30
MS (min) 25.6 ± 28.5 0–60
DAS 28 5.0 ± 1.2 3.5–7.7
PCR ·103 (IU/ml) 190.1 ± 229.3 2.7–1.058.3
ESR (mm/1st h) 41.3 ± 14.1 15–75
Hb (g/dl) 12.0 ± 0.9 10.9–15.2
WBC (·103/mm3) 5.0 ± 1.8 2.5–10.7
PLT (·103/mm3) 214.5 ± 55.6 132–378
ALT (U/L) 60 ± 54 17–294
AST (U/L) 59 ± 50 22–259
Urea (mg/dl) 32.8 ± 8.4 19–46
Creatinine (mg/dl) 0.7 ± 0.2 0.4–1.4
HCV: hepatitis C virus, EHM: extra-hepatic manifestations, MS: morning stiffness, DAS28: disease activity score in 28 joints, PCR: polymerase
chain reaction, ESR: erythrocyte sedimentation rate, Hb: hemoglobin, WBC: white blood cells, PLT: platelets, ALT: alanine transaminase,
AST: aspartate transaminase.
Table 2 Characteristics of the 27 HCV patients at baseline and at the end of follow up.
Characteristic Before INF After INF p
Joint aﬀection 23 (85.2) 23 (85.2) 1
Skin rash 4 (14.8) 5 (18.5) 1
Fatigue 25 (92.6) 10 (37) <0.0001
Peripheral neuropathy 4(14.8) 5 (18.5) 1
Cryoglobulin 5 (18.5) 4 (14.8) 1
PCR positivity 27 (100) 10 (37) <0.0001
PCR count ·103 (IU/ml) 190.1 ± 229.3 104.3 ± 91.9 0.2
Elevated liver enzyme 16 (59.2) 10 (37) 0.03
ALT level 60.3 ± 54.6 48.5 ± 51.8 0.02
Abnormal kidney function 2 (7.4) 3 (11.1) 1
Elevated ESR 19 (70.4) 14 (51.9) 0.1
Leucopenia 7 (25.9) 10 (37) 0.4
Thrombocytopenia 1 (3.7) 8 (29.6) 0.01
PCR: polymerase chain reaction; ALT: alanine transaminase; ESR: erythrocyte sedimentation rate. All values are presented as number
(percentage) except the PCR count and serum ALT levels as mean ± SD.
Effectiveness of peg-IFN/ribavarin therapy 55response (SVR) and 4 (from a total of 16) (25%) had complete
biochemical response. Concerning the clinical response; 2
patients (7.4%) were complete clinical responders (CR), 5
patients (18.5%) were partial responders (PR), 3 patients
(11.1%) showed relapse and 17 (63%) were non-responders
(NR) (Fig. 1).
A comparison of DAS28 score interpretations before and
after (AVT) among the 23 patients with joint arthropathy
showed a p value of 0.05. Final DAS 28 response criteria (joint
response) revealed: 2 patients only (8.7%) had a good joint
response, 7 (30.4%) had a moderate joint response, while 14
(60.8%) had no response. Joint affection showed improvement
in only 2 patients (8.6%) of 23, while 2 patients free of joint
affection developed arthropathy with AVT; 1 developed
arthritis in both knees and 4 PIPs and the other patient devel-
oped arthralgias of all PIPs. 23 patients had joint arthropathy
(85.5%). 13/23(56.5%) had bilateral symmetric non-deformingpolyarthritis and asymmetric oligoarthropathy was noticed in
10 patients (43.4%). 4 patients had peripheral neuropathy
(PN); 3 showed stationary course of PN and one became
worse. The percentage change in liver enzymes, PCR positiv-
ity, fatigue, cryoglobulins, peripheral neuritis, skin affection
and arthropathy is presented in Fig. 2. The 23 patients with
joint affection were treated with anti-inﬂammatory or disease
modifying anti-rheumatic drugs for a variable duration before
and during AVT. These regimens included NSAIDs (n= 23),
steroids (n= 5), methotrexate (n= 6), hydroxychloroquine
(n= 22) and sulfasalazine (n= 5). All 5 patients with vasculi-
tis were initially treated with steroids, 3 patients were treated
with azathioprine, 2 patients with cyclophosphamide and
plasmapheresis.
Compared with values before AVT, patients with SVR had
a signiﬁcant decrease in ALT levels (p= 0.005), and DAS28
(p= 0.02) at the end of follow up. Biochemical response was
Table 3 Individual clinical characteristics of the 27 HCV patients at baseline and at the end of follow up and their clinical and viral
responses.
No. Clinical manifestations Cryoglobulins Clinical response Viral response
Before AVT After AVT Before AVT After AVT
1 A A   NR NR
2 A, R A, R   PR NR
3 A A   NR CR
4 A A   NR CR
5 A A   Relapse CR
6 A A   PR CR
7 A A   PR CR
8 A, S A, S + + NR NR
9 A A   NR NR
10 A A, S  + NR CR
11 A A   Relapse CR
12 A A   NR CR
13 A A   NR NR
14 N, S N, S, A +  NR CR
15 A A, N + + NR NR
16 N, S N, S, R   NR NR
17 N N + + NR NR
18 A A   PR CR
19 A   CR CR
20 A A   NR Relapse
21 A, R A, R   PR NR
22 A A   Relapse CR
23 A A   NR CR
24 A A   NR NR
25 N, S N, S, A +  NR CR
26 A   CR CR
27 A A   NR Relapse
AVT: anti-viral therapy; A, arthropathy; R, renal affection; S, skin disease; N, nerve involvement; , negative; +, positive; CR, complete
response; PR, partial response; NR, no response.
Figure 1 Clinical response of HCV patients after anti-viral
therapy.
56 A.K. El-Garf et al.signiﬁcantly related to viral response (p= 0.02) (Table 4),
while clinical response (p= 0.4) and joint response (p= 0.4)
were not. Joint response was signiﬁcantly related to DAS28
interpretation before AVT (p= 0.01). Clinical response was
signiﬁcantly related to ESR before AVT (p= 0.01) and RF
(p= 0.02), but not signiﬁcantly related to cryoglobulins
(p= 0.3). ALT was positively correlated with PCR count
before AVT (p= 0.000, r = 0.6) and after treatment(p< 0.0001, r= 0.6). Steroids, immunosuppressive drug use
and plasmapheresis did not affect clinical response (p= 0.07,
0.2, 0.7 respectively), nor did they affect viral response
(p= 0.3, 0.1, 0.1 respectively).
Antiviral treatment developed some minor side effects in 13
(48.1%) patients such as anemia (n= 5), mild thrombocytope-
nia (n= 8), ﬂu-like symptoms (n= 7) and mild depression
(n= 1). After a mean follow up of 16.5 months (range 6–
30 months) 26 of 27 patients were alive and continued to be
followed up as outpatients. One patient with polyarteritis
nodosa (PAN) died (3.7%) 11 months after the last dose of
Peg-IFN due to rapid rising creatinine. She was a clinical
and virological non-responder.
4. Discussion
An estimated 130–170 million people are infected with hepati-
tis C worldwide leading to signiﬁcant morbidity, mortality,
and ﬁnancial burden on healthcare [14]. Out of 100 people
who contract the infection, 75–85% will develop chronic infec-
tion, 60–70% will develop chronic liver disease, 5–20% will
develop cirrhosis over the course of their chronic infection,
and 1–5% will die of complications including hepatocellular
carcinoma (HCC) [15]. Egypt faces the largest burden of
HCV infection in the world with a 10% prevalence of chronic
hepatitis C infection among persons aged 15–59 years, pre-
dominantly genotype 4 [16]. The HCV epidemic is particularly
Figure 2 Percentage change of HCV patient characteristics after anti-viral therapy.
Table 4 Relation between biochemical and viral responses in
HCV patients to anti-viral therapy.
Biochemical response Viral response p
Complete Relapse NR
Complete 2 0 2 0.02
Partial 4 0 2
No response 0 0 4
Relapse 0 2 0
NR= no response.
Effectiveness of peg-IFN/ribavarin therapy 57devastating in Egypt where the prevalence of HCV infection is
about 12% [4,5]. Because of its ability to activate the immune
system yet avoid elimination, chronic infection can result in
accumulation of immune complexes and stimulate antibodies,
which can result in extrahepatic conditions [17]. The many
rheumatologic manifestations associated with chronic HCV
infection include arthralgia, myalgia, arthritis, vasculitis, and
sicca syndrome [18]. This was in agreement with the ﬁndings
of the work of El Garf et al. [19] who studied the prevalence
of anti-HCV antibodies among patients admitted to the
rheumatology department, Cairo University hospitals over a
6-month period. They found that the rheumatic manifestations
of chronic HCV represent the primary cause of admission in
7% of all admitted patients. HCV screening should be included
in the routine investigations for patients presenting to rheuma-
tology departments in countries with a high prevalence of
chronic HCV infection.
The goal of antiviral HCV therapy is to cure the infection.
This aim can be achieved in a great number of patients with
combination treatment of pegylated interferon and ribavirin
[11]. HCV therapy has been revolutionized by the approval
of two direct-acting antiviral agents for use in genotype 1
HCV, the protease inhibitors boceprevir and telaprevir [12].
This study aimed to assess the efﬁcacy and safety of combined
pegylated interferon and ribavirin therapy in the management
of rheumatological EHMs in HCV patients.The result of this study revealed that 15 patients (55.5%)
had SVR, but only two patients (7.4%) were complete clinical
responders (CR), 5 (18.5%) were partial responders (PR), 3
(11.1%) showed relapse and 17 (63%) were non-responders
(NR). Also, although biochemical response was signiﬁcantly
related to viral response (p= 0.02); clinical response
(p= 0.4) and joint response (p= 0.4) were not. Joint response
revealed: 2 patients only (8.7%) had a good joint response, 7
(30.4%) had a moderate response, while 14 (60.8%) had no
response.
In our study 23 patients had joint arthropathy (85.5%).
13/23 patients (56.5%) had bilateral symmetric non-deforming
polyarthritis and 10 (43.4%) had asymmetric oligoarthropa-
thy. Their DAS 28 ranged from 3.5 to 7.7 (5 ± 1.2). Most of
these patients were from the Rheumatology and
Rehabilitation outpatient clinic and inpatient department,
Faculty of Medicine, Cairo University Hospitals; this is possi-
bly responsible for a higher incidence of frank arthritis in our
study population, along with a more severe form of disease
than that reported by others [20]. In our study, a comparison
of DAS 28 score interpretations before and after antiviral
treatment among the 23 patients with joint arthropathy
revealed: 2 patients (8.6%) had a good joint response, 7
(30.4%) had a moderate joint response, while 14 (60.8%)
had no response and in 9 (39.1%)of those 14 patients DAS
28 after AVT was worse than before starting it. Similar to
our results, in 2005 Nissen and his colleagues [12] performed
a retrospective study on 62 patients with rheumatological
manifestations of hepatitis C, they concluded that 45
(72.5%) had received interferon-alpha and 39 responded to
the question on its clinical effects. Only three (7.7%) reported
an amelioration, 12 (30.8%) no change, 14 (35.9%) an aggra-
vation and the ﬁnal 10 (25.6%) developed new inﬂammatory
rheumatological symptoms [12]. In our study, of the ﬁve
patients with mixed cryoglobulinemic vasculitis; two only
had SVR and their cryglobulins became negative, yet all of
them showed no clinical response. These results were consis-
tent with those of Levine et al. [21] and Landau et al. [22]
who concluded that patients may show the persistence of cryo-
globulins or symptoms even after the clearance of HCV RNA.
58 A.K. El-Garf et al.These results differ from that in a larger study by Saadoun and
his colleagues [23]; who found different clinical response rates
with AVT; Terrier and Cacoub [24] stated that virologic
response to combined Peg-IFN and ribavirin is 50–60%.
Also, Mazzaro et al. [25] and Cacoub et al. [26] demonstrated
that in HCV-associated mixed cryoglobulinemia combined
Peg-IFN+ RBV therapy leads to a SVR rate similar to that
of HCV-infected patients without, and strongly suggested this
combination as the ﬁrst-line treatment for MCS patients.
Antiviral treatment is sometimes associated with major
immune-mediated adverse events, such as peripheral sensory-
motor neuropathy, thyroiditis, rheumatoid-like polyarthritis,
and other vasculitic manifestations [27–32]. In the study of
Ta˘na˘sescu and Ionescu [33], they reported that the most fre-
quent EHM encountered as a result of the interferon therapy
were peripheral neuropathy and articular involvement and
sometimes rheumatoid-like arthritis. These results were in
agreement with our study after AVT. Similar to our results,
Pietrogrande and associates reported that the presence of cryo-
globulins did not affect the response to AVT [34]. However,
clinical peripheral neuropathy was reported to be of high
prevalence (45%) in another study on 80 newly diagnosed
Egyptian HCV patients, and was found to be associated with
cryoglobulinemia; 18 (22.5%) had subclinical neuropathy [35].
To conclude, the use of Peg IFN and ribavirin did not
improve HCV rheumatological extrahepatic manifestations.
Antiviral treatment may also induce or worsen autoimmune
disorders and is sometimes associated with major immune-me-
diated adverse events. For this reason this approach should be
prescribed only when required by the coexistent liver disease
and should be very carefully administered to patients with
mixed cryoglobulinemia-related peripheral neuropathy or
active skin ulcers.Conﬂict of interest
None.
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